Abstract
Mucin-type O-glycans are upregulated and aberrantly glycosylated in many carcinomas. O-glycan Core 1 (Galβ1-3GalNAcα-O-), also called Thomsen-Friedenreich disaccharide, is a cryptic structure overexpressed in cancer cells through modification of its glycosyltransferase profile. This molecule is a useful model for study of carbohydrate immunogenicity as well as a candidate for active specific immunotherapy of cancer patients. Several strategies are discussed for enhancing immune response to a particular region of carbohydrate: carbohydrate-protein conjugation, linkers, synthetic clustered sugars, chemical modifications, peptide / protein mimetics, and molecular rotation.
Keywords: thomsen-friedenreich disaccharide, mucin-type o-glycans, o-glycan core 1, glycosyltransferase, immunogenicity, carbohydrate-protein conjugation,, synthetic clustered sugars, peptide/protein mimetics, molecular rotation
Current Cancer Drug Targets
Title: Thomsen-Friedenreich Disaccharide Immunogenicity
Volume: 3 Issue: 6
Author(s): Fernando J. Irazoqui and Gustavo A. Nores
Affiliation:
Keywords: thomsen-friedenreich disaccharide, mucin-type o-glycans, o-glycan core 1, glycosyltransferase, immunogenicity, carbohydrate-protein conjugation,, synthetic clustered sugars, peptide/protein mimetics, molecular rotation
Abstract: Mucin-type O-glycans are upregulated and aberrantly glycosylated in many carcinomas. O-glycan Core 1 (Galβ1-3GalNAcα-O-), also called Thomsen-Friedenreich disaccharide, is a cryptic structure overexpressed in cancer cells through modification of its glycosyltransferase profile. This molecule is a useful model for study of carbohydrate immunogenicity as well as a candidate for active specific immunotherapy of cancer patients. Several strategies are discussed for enhancing immune response to a particular region of carbohydrate: carbohydrate-protein conjugation, linkers, synthetic clustered sugars, chemical modifications, peptide / protein mimetics, and molecular rotation.
Export Options
About this article
Cite this article as:
Irazoqui J. Fernando and Nores A. Gustavo, Thomsen-Friedenreich Disaccharide Immunogenicity, Current Cancer Drug Targets 2003; 3 (6) . https://dx.doi.org/10.2174/1568009033481714
DOI https://dx.doi.org/10.2174/1568009033481714 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antibodies in Single-Chain Format Against Tumour-Associated Antigens:Present and Future Applications
Current Medicinal Chemistry Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry A Systematic Review and Bioinformatics Study on Genes and micro-RNAs Involving the Transformation of Endometriosis into Ovarian Cancer
MicroRNA Theoretical Modelling of Potential Chk1 Inhibitors
Letters in Drug Design & Discovery Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Editorial [Hot topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Smoking-Related Cardiovascular Diseases (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Editorial [Hot Topic: COX-2 Inhibition in Gastroenterology and Rheumatolgy:Current Challenges and Perspectives for the Future (Executive Editor: Angel Lanas)]
Current Pharmaceutical Design Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy
Current Drug Targets Toxicophoric and Metabolic In Silico Evaluation of Benzimidazole and Phenylbenzamide Derivatives with Potential Application as Anticancer Agents
Drug Metabolism Letters Dendrimers: Nanosized Multifunctional Platform for Drug Delivery
Drug Delivery Letters Dietary Antioxidants and Oxidative Stress from a Human and Plant Perspective: A Review
Current Nutrition & Food Science A Mini Review of qRT-rtPCR Technology Application in Uncovering the Mechanism of Food Allergy and in the Search for Novel Interventions
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Assessment of Poly (vinyl alcohol) Coated Flutamide Nanoparticulates and their Efficacy on Prostate Cancer Cells
Current Drug Delivery Environmental Chemicals and Breast Cancer Risk – A Structural Chemistry Perspective
Current Medicinal Chemistry A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor
Anti-Cancer Agents in Medicinal Chemistry Feasibility of Margin Reduction for Level II and III Planning Target Volume in Head-and-Neck Image-Guided Radiotherapy – Dosimetric Assessment via A Deformable Image Registration Framework
Current Cancer Therapy Reviews Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Can We Identify a Subset of Patients with DCIS that can be Treated by Wide Excision Alone?
Current Cancer Therapy Reviews